Evidence map›Paper›PMID 38632190›Full record

ArticleHuman cell2024

Establishment and characterization of novel high mucus-producing lung tumoroids derived from a patient with pulmonary solid adenocarcinoma.

Miki Iwai, Etsuko Yokota, Yuta Ishida, Takuro Yukawa, Yoshio Naomoto, Yasumasa Monobe, Minoru Haisa, Nagio Takigawa, Takuya Fukazawa, Tomoki Yamatsuji

Open access · hybridAbstract read
In one paragraph

Article in Human cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Miki IwaiGeneral Medical Center Research Unit, Kawasaki Medical School, Okayama, Japan.
Etsuko YokotaDepartment of General Surgery, Kawasaki Medical School, Okayama, Japan.
Yuta IshidaDepartment of General Surgery, Kawasaki Medical School, Okayama, Japan.
Takuro YukawaDepartment of General Surgery, Kawasaki Medical School, Okayama, Japan.
Yoshio NaomotoDepartment of General Surgery, Kawasaki Medical School, Okayama, Japan.
Yasumasa MonobeOkayama Medical Laboratories Co., Ltd., Kurashiki, Japan.
Minoru HaisaKawasaki Medical School General Medical Center, Okayama, Japan.
Nagio TakigawaGeneral Medical Center Research Unit, Kawasaki Medical School, Okayama, Japan.
Takuya FukazawaGeneral Medical Center Research Unit, Kawasaki Medical School, Okayama, Japan. fukazawat@aol.com.ORCID http://orcid.org/0000-0003-2890-0599
Tomoki YamatsujiDepartment of General Surgery, Kawasaki Medical School, Okayama, Japan.
Kawasaki Medical School · JP

Funding

The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan 22H03164
6 · The paper itself

Abstract

Among mucus-producing lung cancers, invasive mucinous adenocarcinoma of the lung is a rare and unique subtype of pulmonary adenocarcinoma. Notably, mucus production may also be observed in the five subtypes of adenocarcinoma grouped under the higher-level diagnosis of Invasive Non-mucinous Adenocarcinomas (NMA). Overlapping pathologic features in mucus-producing tumors can cause diagnostic confusion with significant clinical consequences. In this study, we established lung tumoroids, PDT-LUAD#99, from a patient with NMA and mucus production. The tumoroids were derived from the malignant pleural effusion of a patient with lung cancer and have been successfully developed for long-term culture (> 11 months). Karyotyping by fluorescence in situ hybridization using an alpha-satellite probe showed that tumoroids harbored aneuploid karyotypes. Subcutaneous inoculation of PDT-LUAD#99 lung tumoroids into immunodeficient mice resulted in tumor formation, suggesting that the tumoroids were derived from cancer. Xenografts from PDT-LUAD#99 lung tumoroids reproduced the solid adenocarcinoma with mucin production that was observed in the patient's metastatic lymph nodes. Immunoblot analysis showed MUC5AC secretion into the culture supernatant of PDT-LUAD#99 lung tumoroids, which in contradistinction was barely detected in the culture supernatants of NCI-A549 and NCI-H2122 pulmonary adenocarcinoma cells known for their mucin-producing abilities. Here, we established a novel high-mucus-producing lung tumoroids from a solid adenocarcinoma. This preclinical model may be useful for elucidating the pathogenesis of mucus-producing lung cancer.

Indexed as

AdenocarcinomaAdenocarcinoma of LungLung NeoplasmsMucin 5ACMucusAdenocarcinoma, MucinousAnimalsCell Line, TumorHumansMaleMiceTumor Cells, CulturedMUC5AC protein, humanMucin 5ACInvasive mucinous adenocarcinomaMucus-producing lung cancerPulmonary adenocarcinomaTumoroids, preclinical cancer model

Identifiers

PMID38632190
PMCPMC11194211
OpenAlexW4394872422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.